Atopic Dermatitis Now has Effective Cure; Pfizer Receives Approval for Eucrisa from FDA

FDA confirmed that the new drug called "crisaborole" will be available in the drug stores under the brand name Eucrisa.

Due to increasing environmental pollution and changing social habits, skin disorders are spreading faster these days. The new topical drug seems to be an accurate solution to many dermatitis itching cases.

Atopic dermatitis is known to be one of the most common of the many different sorts of eczema.  The skin disorder hits a person in his childhood and lasts throughput the adulthood.

Atopic dermatitis is a skin disorder and it distorts the skin color, texture and natural gloss. Bumps appear on the skin which are red, crusted, and scaly. The worst thing about atopic dermatitis is that it is extremely itching.

The drug's efficacy is tested and has shown to be highly successful treatment plan. The patients who applied the drug on their affected areas of skin experienced full or major cure in just 28 days reports Reuters.

No long lasting or drastic side effects were experienced while the experimental treatment continued.  The only side effect was site pain like stinging or burning said the agency.  

Atopic dermatitis has not yet an efficient drug which is why the market for the new drug Eucrisa is large.

Pfizer has purchased this year Anacor Pharmaceuticals for $5.2 billion and the drug is going to be in its portfolio. The estimated annual peak sale of the drug is supposed to generate about $2 billion according to Market Business Insider.  

For the more severe cases of atopic dermatitis injectable drug dupilumab is needed. Sanofi and Regeneron Pharmaceuticals are awaiting the approval decision from FDA for dupilumab.

The more severe condition can be like poison ivy permanent rush with skin damage and intense itching

The approval of Eucrisa is an important milestone in better and more effective cure to skin disorders.